Limbix is actively researching and productizing therapies for a new therapeutic class: Prescription Digital Therapeutics. PDTs require strict compliance with FDA quality management standards, are put through rigorous research trials, and in certain cases can be paired with existing pharmacological treatments. Upon FDA approval, PDTs support medical claims and can be prescribed similarly to traditional drugs.
Skip Rizzo, Ph.D., mentioned above, is also one of the consultants for the Limbix team.
Their current directions are aimed at:
- Adolescent Depression;
- Major Depressive Disorder;
- Social Anxiety;
- Panic Disorder;
- Chronic Pain
- Adolescent Social Anxiety;
- Alcohol Use Disorder;